

**TO
THE
SHAREHOLDERS OF
TCHAIKAPHARMA HIGH QUALITY MEDICINES INC.
SOFIA, BULGARIA**

***DECLARATION under Art. 100n,
para. 4, item 3 of the Public
Offering of Securities Act***

Undersigned:

Asen Kostov Kitov in my capacity as a registered auditor (with Reg. No 0234 of the register of ICPA under Art. 20 of the Independent Financial Audit Act) **hereby declare that**

I was engaged to carry out the statutory audit of the consolidated financial statements of "Tchaikapharma high quality medicines" Inc. for 2021, compiled in accordance with the International Financial Reporting Standards adopted by the EU, a common name of the accounting basis, as defined in *item 8 of the AR of the Accounting Act* under the name "International Accounting Standards", **and that** I am responsible for the audit commitment on my own behalf/on behalf of "AK Consult" Ltd company/.

As a result of the audit I made, I issued an audit report on 21.04.2022.

I HEREBY CONFIRM that as reported in my audit report on the annual consolidated financial statements of Tchaikapharma High Quality Medicines Inc. for 2021, prepared on 18.04.2022:

- 1. Art. 100n, para. 4, item 3, letter "a" Auditor's opinion:*** In my opinion, the accompanying consolidated financial statements present fairly, in all material aspects, the financial position of the Company as of December 31, 2021 and its financial results from its activities and cash flows for the year ending on that date, in accordance with the International Financial Reporting Standards (IFRSs) as adopted by the European Union (EU).
- 2. Art. 100n, para. 4, item 3, letter "b" Information relating to the transactions of Tchaikapharma High Quality Medicines Inc. with related parties.*** Information on related party transactions is duly disclosed in the Appendix to the consolidated financial statements. Based on the audit procedures I carried out for related party transactions as part of the audit of the consolidated financial statements as a whole, I was not aware of facts, circumstances or other information that would lead me to conclude that any related party transactions have not been disclosed in the accompanying financial statements for the year ended December 31, 2021, in all

material respects, in accordance with the requirements of IAS 24 *Related Party Disclosures*. The results of my audit procedures for related party transactions have been reviewed by me in the context of forming my opinion on the financial statements as a whole, not for the purpose of expressing a separate opinion on related party transactions.

3. Art 100n, para. 4, item 3, letter "c" Information relating to material transactions.

My audit responsibilities for the consolidated financial statements as a whole, described in the section "Auditor's Responsibilities for the Audit of the consolidated Financial Statements" of my report, include evaluating whether the financial statements present material transactions and events in a manner that achieves fair presentation. Based on the audit procedures performed by me on the material transactions underlying the consolidated financial statements for the year ended December 31, 2021, I was not aware of any facts, circumstances or other information from which I could conclude that there were cases of material misstatement and disclosure in accordance with the applicable IFRS requirements adopted by the European Union. The results of my audit procedures on the Company's material transactions and events are considered by me in the context of forming my opinion on the financial statements as a whole and not in order to express a separate opinion on those material transactions.

The representations made with this declaration should be considered only in the context of the audit report issued by me on 21.04.2022 as a result of the independent financial audit of Tchaikapharma High Quality Medicines Inc.'s financial statements for the reporting period, ending on 31.12.2021, compiled on 18.04.2022. This declaration is intended solely for the above-mentioned addressee and has been prepared solely and only to fulfill the requirements set out in Art. 100(n), para. 4, item 3 of the Public Offering of Securities Act (POSA) and should not be taken as a substitute for my conclusions contained in the audit report issued by me on 21.04.2022 regarding the issues covered by Art. 100(n), item 3 of POSA.

Auditor:

(Asen Kitov, Registered auditor)

Sofia, Bulgaria, 35 Trakia str., 2nd floor, office 6
21.04.2022